Monday, October 06, 2014 8:51:40 AM
ITUS Subsidiary Receives Claims Construction Ruling
Marketwired
ITUS Corporation October 3, 2014 7:00 AM
MELVILLE, NY--(Marketwired - October 03, 2014) - ITUS Corporation ("ITUS") (ITUS), a company that builds and protects innovation, today announced that its wholly owned subsidiary, Secure Web Conference Corporation ("SWCC"), received a unfavorable ruling from the US District Court for the Eastern District of New York in its patent infringement lawsuit against Microsoft Corporation in connection with SWCC's patented Key Based Web Conferencing Encryption technology. In its claims construction ruling, the Court construed several key patent claim terms in a manner adverse to SWCC.
Robert Berman, ITUS's President and CEO stated, "I often tell investors that patent infringement lawsuits are highly technical and complicated, which is why so many decisions are over turned on appeal. I also emphasize that our business model is to diversify, so that we are not overly dependent on any one lawsuit. We have 17 other lawsuits across 4 patented technologies, and many more in the pipeline. Although we would have preferred the Court to rule in our favor, the end result is that we have plenty of lawsuits and patented technologies to sustain our business."
A claims construction hearing is part of a patent infringement lawsuit in which the Court gives meaning to certain patent claim terms that are in dispute. Appeals of claims construction orders are heard by the United States Court of Appeals for the Federal Circuit on a de novo basis, meaning without deference to the lower Court's decision. SWCC will evaluate its options for appeal to the Federal Circuit, and in the interim, will suspend lawsuits against Apple AT&T, and Citrix, which also rely on the language construed by the Court.
Recent ANIX News
- Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024 • PR Newswire (US) • 04/30/2024 11:45:00 AM
- Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board • PR Newswire (US) • 04/18/2024 12:20:00 PM
- Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties • PR Newswire (US) • 03/14/2024 12:45:00 PM
- Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress • PR Newswire (US) • 03/11/2024 12:00:00 PM
- Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial • PR Newswire (US) • 02/12/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/08/2024 09:15:32 PM
- Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference • PR Newswire (US) • 01/29/2024 01:50:00 PM
- Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology • PR Newswire (US) • 01/23/2024 12:55:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:08:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:07:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:07:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:05:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:05:16 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/16/2024 10:29:43 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/16/2024 09:43:17 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 01/16/2024 09:30:49 PM
- Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024 • PR Newswire (US) • 01/10/2024 02:00:00 PM
- Anixa Biosciences to Present at Biotech Showcase 2024 • PR Newswire (US) • 12/14/2023 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 11:01:47 AM
- Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine • PR Newswire (US) • 12/06/2023 11:00:00 PM
- Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine • PR Newswire (US) • 12/06/2023 09:05:00 PM
- Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology • PR Newswire (US) • 11/27/2023 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/02/2023 02:58:20 PM
- Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference • PR Newswire (US) • 10/31/2023 12:30:00 PM
- Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board • PR Newswire (US) • 10/23/2023 12:30:00 PM
FEATURED Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM